US filing the first worldwide for JT/GSK's MEK inhibitor for melanoma
This article was originally published in Scrip
Executive Summary
Japan Tobacco's trametinib has been filed for approval in the US by global licensee GlaxoSmithKline, for the treatment of unresectable or metastatic melanoma. The filing is the first to be made worldwide for the MEK inhibitor, JT in Japan told Scrip.